AI Article Synopsis
- The TGF-β superfamily is crucial for various bodily functions and is disrupted in diseases like pancreatic cancer, known for its high mortality rate and treatment challenges.
- Current pancreatic cancer treatments often fail due to tumor resistance and late diagnosis, prompting interest in immunotherapies, with TGF-β emerging as a key target.
- This review explores TGF-β's role in pancreatic cancer, assesses existing therapies aimed at the TGF-β superfamily, and suggests future strategies for targeting TGF-β signaling pathways.
Article Abstract
The transforming growth factor (TGF)-β superfamily has important physiologic roles and is dysregulated in many pathologic processes, including pancreatic cancer. Pancreatic cancer is one of the most lethal cancer diagnoses, and current therapies are largely ineffective due to tumor resistance and late-stage diagnosis with poor prognosis. Recent efforts are focused on the potential of immunotherapies in improving therapeutic results for patients with pancreatic cancer, among which TGF-β has been identified as a promising target. This review focuses on the role of TGF-β in the diseased pancreas and pancreatic cancer. It also aims to summarize the current status of therapies targeting the TGF-β superfamily and postulate potential future directions in targeting the TGF-β signaling pathways.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944957 | PMC |
| http://dx.doi.org/10.3389/fonc.2024.1362247 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!